胃肠道间质瘤药物治疗和耐药机制研究进展
Research progress on drug treatment and drug resistance mechanism of gastrointestinal stromal tumors
赵全铭 1杨满斗 1胡义波 1苏有橦 1普丽 1章瑜 1李文亮1
作者信息
- 1. 昆明医科大学附属第三医院胃与小肠外科,昆明 650000,云南
- 折叠
摘要
胃肠道间质瘤(GIST)是胃肠道最常见的间叶源性肿瘤.酪氨酸激酶抑制剂(TKI)是G IST治疗的基石,但耐药基因的突变给治疗带来了很多问题,特别是KIT耐药突变的异质性是一个主要的挑战.近年来,随着多项GIST相关药物研究的完成,揭示靶向治疗、免疫治疗、联合治疗在不同方向上治疗GIST的巨大潜力,为GIST提供更多的治疗选择.本文将从近年来的实验研究和未来方向两个方面进行综述.
Abstract
Gastrointestinal stromal tumors(GIST)are the most common mesenchymal-derived tu-mors of the gastrointestinal tract.Tyrosine kinase inhibitors(TKIs)are the cornerstone of GIST thera-py,but mutations in resistance genes pose many problems for treatment,especially the heterogene-ity of KIT resistance mutations.In recent years,with the release of a number of GIST related drug research and experimental results,the great poten-tial of targeted therapy,immunotherapy and com-bination therapy to treat GIST in different direc-tions has been revealed,providing more therapeu-tic directions for GIST.This article will review the experimental research and future direction in re-cent years.
关键词
胃肠道间质瘤/药物治疗/耐药机制/研究进展Key words
stromal tumors of the gastrointesti-nal tract/drug therapy/drug resistance mecha-nisms/research progress引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
维普
万方数据